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Introduction: Alzheimer’s disease (AD) is a long term progressive neurodegenerative dis-
ease and might affect the retinal nerve fiber layer thickness (RNFLT) of the eye. There
is increasing evidence that visual evoked potentials (VEP), which are an objective way to
indicate visual field loss, might be affected by the disease as well.
Materials and Methods: About 22 patients (mean age: 75.9±6.1 years; 14 women) with
mild-to-moderate AD and 22 sex-matched healthy patients were examined. We compared
the use of VEP and RNFLT using the latest high-resolution spectral domain optical coher-
ence tomography with eye-tracking capabilities for optimized peripapillary scan centering
for the first time in AD patients.
Results: The mean MMSE score was 22.59±5.47 in the AD group, and did not signifi-
cantly correlate with the VEP latencies. We found no significant difference between the
VEP latencies of the AD patients and those of the control patients. No peripapillary sector
of the retina had a RNFLT significantly correlated with the VEP latencies.
Discussion: We demonstrated that pattern VEP did not show any significant correlation
despite subtle loss in RNFLT. It remains open whether additional flash VEP combined with
RNFLT analysis may be useful in diagnosing AD, particularly for mild-to-moderate stages
of the disease.
Keywords: Alzheimer’s disease, dementia, retinal nerve fiber layer thickness, visual evoked potentials, optical
coherence tomography
INTRODUCTION
Alzheimer’s disease (AD) is described as a long term progressive
neurodegenerative disease and characterized by a large inter-
subject variability. The pathogenesis of AD is still an open debate.
In most cases, the clinical diagnosis of AD is made early enough
and is accurate, however paraclinical support would be useful for
all cases, and even more so if the disease course, namely neurode-
generative changes and therapeutic effects, could be monitored
and objectified over time. Drugs which have been used for the
therapy of AD might be most effective in the early stages of the
disease (1). Traditional neuro-imaging diagnostics including mag-
netic resonance imaging (MRI) to show the atrophy of the medial
temporal lobe (2, 3), positron emission tomography (PET) to
detect changes in the metabolism of glucose (3, 4) and the Aβ
storage (5, 6), and the cerebrospinal fluid analysis (CSA) to mea-
sure the biomarkers for tau protein and Aβ levels (7, 8) have only
limited value (9).
A new ophthalmic imaging method called optical coherence
tomography (OCT) has been considered to be useful for the detec-
tion of early stages of AD (10–12). OCT provides cross-section
imaging of the retina and is able to measure the retinal nerve fiber
layer thickness (RNFLT) (13, 14). It has been used for the diagno-
sis of many diseases of the retina and various optic neuropathies,
including glaucoma (15–22). The human eye is an embryological
protrusion of the brain, and the nerves and axons of the retinal
nerve fiber layer are similar to those of the brain. This leads to the
question of whether AD might also affect the RNFLT of the eye. For
many years histopathological studies have shown that the RNFLT
is not affected by AD (23, 24). In contrast to this, recent OCT
studies, claimed to be able to detect a loss of the RNFLT in patients
with AD (11, 12, 25–27). However, those studies were performed
using conventional OCT technology, lacking reliable optic nerve
scan centering (21), a subject to potential misinterpretation in a
number of cases (21). Studies showed that OCT measurements
of the RNFLT were associated with mild cognitive impairment
(MCI), and this could be taken to discriminate between different
stages of AD (10–12).
Visual evoked potentials (VEP) are an objective way to indicate
visual field loss (28–31). They represent the visual cortex activity, as
they are a reaction to the visual information that is passing through
the optical media of the eye which gets processed by the retina
and the genicula-striate pathway. The occurring evoked response
shows the performance of the visual system until that point. There
are numerous studies discussing the use of VEP in AD. Some stud-
ies have shown that AD patients have longer latencies of flash
VEP (32–34). Contrary to this, other studies showed normal pat-
tern VEP while the RNFLT, as measured with conventional OCT
technology, presented abnormal in AD patients (11).
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The purpose of this study was to compare the use of VEP and
RNFLT using the latest high-resolution spectral domain optical
coherence tomography (SD-OCT) with eye-tracking capabilities
for optimized peripapillary scan centering for the first time in AD
patients. The goals were to show (i) whether there is any change of
VEP in AD patients as compared to sex-matched controls, and (ii)
to correlate those latencies with the RNFLT of the AD patients.
MATERIALS AND METHODS
About 42 eyes of 22 patients (mean age: 75.9± 6.1 years; 14
women) with mild-to-moderate AD were examined – two patients
had only one eye examined. The control group involved 43 eyes
of 22 sex-matched healthy patients (mean age: 64.0± 8.2 years;
15 women) – one patient had only one eye examined. The study
was approved by the Ethics committee II of the Medical Faculty
Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim,
Germany and followed the ethical principles of the Declaration of
Helsinki. Before the examinations, informed consent was obtained
from each patient. In case the patient was incompetent of giving
informed consent, the care giver (spouse or adult child) declared
their approval.
Alzheimer’s disease was diagnosed by a physician and a multi-
professional team (neurologists, psychiatrists, psychologists) at the
Memory Clinic of the Department of Geriatric Psychiatry of the
Central Institute of Mental Health, Mannheim, Germany. The
assessments consisted of the medical history from the patient and
caregiver, general exams, laboratory, neuropsychological, and radi-
ologic tests. To indicate progressive cognitive decline of everyday
functioning and to show the absence of any neurological or psychi-
atric disorder possibly causing dementia (other than AD) general
physical, neurological, and neuropsychological examinations were
performed. The laboratory testing included complete blood count
with differential counts, syphilis screening, serum electrolytes, liver
and renal function, cholesterol status, thyroid function, serum vit-
amin B12, and folate levels. This way secondary causes of dementia
were excluded. The neuropsychological tests (CERAD test battery
WMS-LM, TMT-A and -B) were used to show an impairment in
one or two more clinical domains severe enough to cause impair-
ment in activities of daily life. For radiologic testing MRI was used
to show a visual rating of evidence of medial temporal lobe atro-
phy and absence of major white matter abnormalities and/or other
cerebrovascular disorders. In addition to that most patients had
lowered Aβ 42 peptide and accelerated tau and/or phospho-tau in
cerebrospinal fluid (which is typical for AD).
The patients’ history and medical records were carefully
reviewed for diseases possibly affecting the RNFLT. Only patients
meeting inclusion and exclusion criteria were included. The oph-
thalmic inclusion criteria were (i) best-corrected visual acuity
of 0.3 LogMAR or better, (ii) spherical refraction within ±5.0
diopters (D), (iii) cylindrical correction within ±2.0 D, and
(iv) normal results for visual field testing (Swedish Interactive
Thresholding Algorithm SITA; Octopus 101 Perimeter; Haag-
Streit Deutschland GmbH, Wedel, Germany). The exclusion cri-
teria were (i) intensive alcohol abuse, (ii) body mass index >30,
(iii) intraocular pressure≥21 mmHg, (iv) history of glaucoma, (v)
anterior ischemic optic neuropathy, (vi) high myopia, (vii) prior
ocular surgery, and (viii) congenital abnormal abnormalities of
the optic nerve.
Patients underwent various ophthalmic examinations: (i)
assessment of best-corrected visual acuity by auto-refractometry
(OCULUS/NIDEK auto-refractometer, OCULUS Optikgeräte
GmbH, Wetzlar, Germany) followed by subjective refractome-
try using the ETDRS (Early Treatment of Diabetic Retinopathy
Study) 2000 chart for high-contrast visual acuity, (ii) slit lamp
assisted biomicroscopy of the anterior segment, (iii) ophthal-
moscopy after medical dilation of the pupil, (iv) visual field testing
(Swedish Interactive Thresholding Algorithm SITA; Octopus 101
Perimeter; Haag-Streit Deutschland GmbH, Wedel, Germany), (v)
Goldmann applanation tonometry, (vi) VEP measurement, (vii)
OCT for RNFLT measurement.
The VEP were carried out with ROLAND CONSULT RETI-
port/scan 21 (ROLAND CONSULT, Brandenburg an der Havel,
Deutschland) in abidance of the current guideline for pattern
VEP of the International Society for Clinical Electrophysiology
of Vision (35). The pattern-reversal protocol used black and white
checks changing phase abruptly and repeatedly at a reversal rate of
two reversals per second (±10%) (Each full cycle consists of two
reversals so this equates a frequency of 1.0 Hz.). The checkerboard
stimuli with large 1° (60 min of arc) and small 0.25° (15 min)
checks provided N75 and P100 peaks, where P100 peaks are the
most prominent ones.
The thickness of the RNFLT was measured using latest high-
resolution SD-OCT (SPECTRALIS software version 5.3.3.0, EYE
EXPLORER Software 1.6.4.0; Heidelberg Engineering, Heidelberg,
Germany). This device is a combination of normal SD-OCT and
confocal scanning laser ophthalmoscopy (cSLO). The superlu-
minescence diode of the SD-OCT emits a scan beam with a
wavelength of 879 nm performing up to 40,000 A-scans/s with
a depth resolution of 7µm and a transversal resolution of 14µm.
The cSLO scans point to point with a laser the illuminated retina
and creates this way a real-time reference fundus image. SD-OCT
examinations are fast, inexpensive, objective, and non-dependent
on the cooperation of patient. The SD-OCT has several additional
features that were used in this study: eye-tracking (TrueTrack™;
Heidelberg Engineering, Heidelberg, Germany) locks the SD-OCT
image to the reference fundus capture and enables comparing
repeated measurements. Furthermore, the examination is non-
dependent on the investigator due to the enabled eye-tracking.
The automatic real-time averaging mode (ART) takes additional
B scans in order to improve the quality. Therefore, the device locks
after the first A scan and adds B scans whenever the eye has the
exact same position. These two features combined with the high
speed of the device facilitate reducing artifacts. In our study at
least three high-resolution images with enabled ART mode (with
at least 18 additional frames) were taken. Scans with low fixa-
tion or failing RNFL segmentation were excluded. To minimize
possible variabilities, all images were performed by one examiner.
The criteria for determining the scan quality were: (i) a clear fun-
dus image before and after the acquisition; (ii) absence of scan or
algorithm failures; (iii) even and dense gray scale saturation in all
retinal layers and dense gray visible in retinal pigment epithelium;
and (iv) RNFL visible as a continuous scan pattern.
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FIGURE 1 | Comparison of VEP latencies (N75 and P100) of control
patients (marked as control) and AD patients (marked as AD). No
significant (marked as n.s.) differences were found between the two
groups (P -value >0.05). Data is presented as a Tukey box-and-whiskers plot,
with values that are above or below the whiskers drawn as individual dots.
FIGURE 2 | Comparison of the retinal nerve fiber layer thickness in
different peripapillary sectors: the different sectors are labeled as
follows: global (G), nasal superior (NS), nasal (N), nasal inferior (NI),
temporal inferior (TI), temporal (T), and temporal superior (TS). Data is
presented as a Tukey box-and-whiskers plot, with values that are above or
below the whiskers drawn as individual dots.
Statistical analysis was carried out using a commercially avail-
able software package (Prism 6 for Mac OSX; GraphPad Software,
Version 6.0b). Mean and standard deviations were presented.
P-values were corrected according to Bonferroni to correct for
performing multiple statistical analyses. All P-values were two-
tailed and a P-value <0.05 was considered to indicate statis-
tical significance. Correlation was done using Pearson correla-
tion calculations as values are sampled from populations that
FIGURE 3 | Scatter plot of all N75 latencies in dependence of the
associated global RNFLT. There was no significant correlation found for
N75 latency with global RNFLT in AD patients (r =0.271; P -value=0.222).
FIGURE 4 | Scatter plot of all P100 latencies in dependence of the
associated global RNFLT. There was no significant correlation found for
N75 latency with global RNFLT in AD patients (r =0.322; P -value=0.144).
follow a Gaussian distribution – at least approximately. By cor-
relation coefficient r is meant. VEP comparison and RNFLT
are presented as Tukey box-and-whiskers plots with values that
are above or below the whiskers drawn as individual dots. The
mean of both eyes of each participant was used for statistical
analysis (phenotype). VEP normative data standardization was
established following the guidelines of the International Soci-
ety for Clinical Electrophysiology of Vision (35), resulting in a
95% reference interval as the limit of normal (range from 2.5
to 97.5%).
RESULTS
The study included 42 eyes of 22 patients with AD (mean
age: 75.9± 6.1 years; age range: 66–88 years; 14 women), and
43 eyes of 22 sex-matched healthy control patients (mean age:
64.0± 8.2 years; age range: 53–85 years; 16 women). In both
groups, there was no significant correlation found between male
or female and the right or left eye in RNFLT and VEP latencies (P-
value>0.05). There was no significant correlation of VEP latencies
and RNFLT with the age of the participants in both groups. The
mean MMSE score was 22.59± 5.47 in the AD group, and this
was not significantly correlated with the VEP latencies. We found
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Table 1 | Correlation of N75 and P100 latencies with the RNFLT of the different sectors.
G NS N NI TI T TS
N75 0.271 P =0.222 0.363 P =0.096 0.344 P =0.117 −0.027 P =0.905 0.091 P =0.689 0.068 P =0.763 0.139 P =0.537
P100 0.322 P =0.144 0.194 P =0.386 0.359 P =0.101 0.261 P =0.242 0.155 P =0.491 0.015 P =0.946 0.145 P =0.519
The different sectors are labeled as follows: global (G), nasal superior (NS), nasal (N), nasal inferior (NI), temporal inferior (TI), temporal (T), and temporal superior
(TS).The correlation tests with Bonferroni correction for multiple comparisons showed no significant correlations.The table shows the correlation coefficients and the
P-value below. A P-value <0.05 is considered significant (with Bonferroni correction for multiple comparison in this case a P-value <0.0036 is considered significant).
no significant difference between the VEP latencies of the AD
patients and those of the control patients (P-value>0.05), as pre-
sented in Figure 1. Furthermore, all AD patients had normal VEP
values within the 95% reference interval as the limit of normal
(range from 2.5 to 97.5%). The RNFLT of the AD patients is pre-
sented in Figure 2. Using our previously introduced advanced
gender-matched measurement model, the RNFLT was marked as
pathologic in 32 out of 42 eyes (76.19%) (36). In order to show the
relationship between VEP latencies and RNFLT of the AD patients
globally, we outlined two scatter plots (Figures 3 and 4). No cor-
relation was found between these variables. In more detail, no
peripapillary sector of the retina had a RNFLT that significantly
correlated with the VEP latencies (Table 1; P-value >0.05).
DISCUSSION
Our results showed normal pattern VEP latencies compared to a
sex-matched healthy control group. Furthermore, the RNFLT of
the AD patients did not correlate with pattern VEP latencies.
The use of VEP in AD has been discussed a lot in recent years.
Some studies found abnormal pattern VEP in AD patients (33,
37, 38). In contrast, a number of authors stated that they did not
find any abnormalities in pattern VEP while experiencing abnor-
mal flash VEP (39–43). Nevertheless, flash VEP suffer from a lower
reproducibility compared to pattern VEP (35). One study compar-
ing RNFLT and VEP in AD found normal pattern VEP with abnor-
mal RNFLT, however using conventional OCT technology (11).
The RNFLT has been examined in several studies using histopatho-
logic techniques, with inconsistent findings. Some stated that there
is no decrease (44–48), while others found abnormal RNFLT (23,
24). Additionally, studies using conventional time-domain OCT
technology, lacking eye-tracking capabilities, found only a subtle
RNFLT decrease in AD patients (10–12, 25, 49–51).
The different findings between flash and pattern VEP may
result from the different methodological approach. The functional
organization of the proximal retina and the visual cortex is pref-
erentially sensitive to patterned stimuli (52). As the changes in
RNFLT are mostly subtle and/or subclinical, there may be no
effect in pattern VEP while experiencing abnormal flash VEP.
The disagreement in OCT studies may also evolve from diver-
gent stages of the disease and the technical inaccuracy of post-
mortem histopathological studies. In our case all AD patients had
a mild-to-moderate AD.
Our results implicate that pattern VEP does not show any
changes in AD despite the fact that RNFLT changes demonstrated
as a decrease in one or more peripapillary sectors, were found
in some but not all AD patients. As a consequence, pattern VEP
did not correlate with the RNFLT of AD patients. However, severe
stages of the disease may show further changes. Nevertheless, lit-
erature indicates that the use of flash VEP may be recommended
to show changes in AD.
The limitations of this study were, (i) that no flashVEP was used
to show the difference to pattern VEP, (ii) that only cross-sectional
measurements were done without follow-up to investigate a poten-
tial progression of the RNFLT and VEP, and (iii) that the patients
had a mild-to-moderate AD. On the other hand, the strengths
were that (i) patients and controls were sex-matched, (ii) for
the first time latest high-resolution SD-OCT measurements were
obtained, and (iii) the clinical diagnosis of AD was obtained in a
specialized memory clinic by using highly standardized clinical cri-
teria, including neuropsychological assessments and biomarkers
(MTA, CSF).
In summary, we demonstrated that pattern VEP may not be
useful for diagnosing AD and may not show a correlation despite
subtle loss in RNFLT. It remains unclear whether flash VEP com-
bined with RNFLT analysis may be useful in diagnosing AD, taken
in account that flash VEP have a lower reproducibility compared
to pattern VEP. For further studies, it is important for the interpre-
tation of SD-OCT- and VEP-investigations that the standardized
technical requirements provided by latest SD-OCT technology are
used and the current guidelines are applied.
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